Costs and benefits of combining probation and substance abuse treatment

Journal of Mental Health Policy and Economics

Volumn 9, Issue 2, 2006, Pages 57-70

  Alemi, Farrokh ^a,d   Taxman, Faye ^b   Baghi, Heibatollah ^a   Vang, Jee ^a   Thanner, Meridith ^c   Doyon, Victoria ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d Bureau of Governmental Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HOSPITAL COST; HOSPITALIZATION; HUMAN; INFORMATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HOSPITAL; PRISON; PROBABILITY; PROBATION; PSYCHIATRIC TREATMENT; RECURRENCE RISK; RELIABILITY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; FORENSIC PSYCHIATRY; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MARYLAND; MENTAL HEALTH SERVICES; PRISONERS; SUBSTANCE-RELATED DISORDERS; VIRGINIA;

EID: 33745828687     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Petersilia JM, Turner S. Comparing intensive and regular supervision for high risk probationers: Early results from an experiment in California. Crime Delinq 1990; 36: 87-111.
2. Petersilia JM, Turner S. Intensive probation and parole. In M. Torry (Ed.): Crime and Justice: A review of research. Chicago, University of Chicago Press, 281-336. 1979.
3. Taxman FS, Soule D, Gelb A. Graduated Sanctions: Stepping Into Accountable Systems and Offenders, Prison Journal, 1999.
4. Taxman F and Sherman S. Seamless Systems of Care: Using Automation to Improve Outcomes. In Moriarty and D. Carter (Eds): Criminal Justice Technology in the 21st Century. Springfield, Illinois. Charles C. Thomas, 1998.
5. Shepard DS, Reif S. The value of vocational rehabilitation in substance user treatment: a cost-effectiveness framework. Subst Use Misuse 2004; 39 (13-14): 2581-2609.
6. Kunz FM, French MT, Bazargan-Hejazi S. Cost-effectiveness analysis of a brief intervention delivered to problem drinkers presenting at an innercity hospital emergency department. J Stud Alcohol 2004; 65: 363-370.
7. Kedia S, Perry SW. Substance abuse treatment effectiveness of publicly funded clients in Tennessee. J Natl Med Assoc 2003; 95(4): 270-277.
8. Kaskutas LA, Witbrodt J, French MT. Outcomes and costs of day hospital treatment and nonmedical day treatment for chemical dependency. J Stud Alcohol 2004; 65(3): 371-82.
9. Jofre-Bonet M, Sindelar JL, Petrakis IL, Nich C, Frankforter T, Rounsaville BJ, Carroll KM. Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients. J Subst Abuse Treat 2004; 26(3): 225-232.
10. French MT, Roebuck MC, Dennis ML, Diamond G, Godley SH, Tims F, Webb C, Heffell JM. The economic cost of outpatient marijuana treatment for adolescents: findings from a multi-site field experiment. Addiction 2002; 97 (Suppl 1): 84-97.
11. Doran CM, Shanahan M, Bell J, Gibson A. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug Alcohol Rev 2004; 23(2): 171-175.
12. Dismuke CE, French MT, Salome HJ, Foss MA, Scott CK, Dennis ML. Out of touch or on the money: Do the clinical objectives of addiction treatment coincide with economic evaluation results? J Subst Abuse Treat 2004; 27(3): 253-263.
13. Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, Liddle H, Titus JC, Kaminer Y, Webb C, Hamilton N, Funk R. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J Subst Abuse Treat 2004; 27(3): 197-213.
14. Daley M, Love CT, Shepard DS, Peterson CB, White KL, Hall FB. Cost-effectiveness of Connecticut's in-prison substance abuse treatment. Journal of Offender Rehabilitation 2004; 39(3): 69-92.
15. Caulkins JP, Pacula RL, Paddock S, Chiesa J. What we can-and cannot-expect from school-based drug prevention. Drug Alcohol Rev 2004; 23(1): 79-87.
16. Alemi F, Haack M, Holifield L, Claudio Y, Haqqi K. Unit cost of counseling and patients length of stay in a residential drug treatment setting. J Ment Health Policy Econ 2002; 5(3): 103-107.
17. McCollister KE, French MT, Prendergast ML, Hall E, Sacks S. Long-term cost effectiveness of addiction treatment for criminal offenders. Justice Quarterly 2004; 21: 659-679.
18. McCollister KE, French MT, Inciardi JA, Butzin CA, Martin SS, Hooper RM. Post-release substance abuse treatment for criminal offenders: A cost-effectiveness analysis. Journal of Quantitative Criminology 2003; 19: 389-407.
19. French MT. Economic evaluation of drug abuse treatment programs: methodology and findings. Am J Drug Alcohol Abuse 1995; 21(1): 111-135.
20. Fass SM, Pi CR.Getting tough on juvenile crime: An analysis of costs and benefits. Journal of Research in Crime and Delinquency 2002; 39: 363-399.
21. Aos S. The Juvenile Justice System in Washington State: Recommendations to Improve Cost-Effectiveness. Washington State Institute for Public Policy, October 2002.
22. Aos S, Phipps P, Barnoski R, Lieb R. The Comparative Costs and Benefits of Programs to Reduce Crime, v 4.0. Washington State Institute for Public Policy, May 2001. Available on 04/18/2006 at http://www.nicic.org/ Library/020074.
23. Aos S, Lieb R, Mayfield J, Miller M, Pennucci A. Benefits and Costs of Prevention and Early Intervention Programs for Youth. Washington State Institute for Public Policy, September. 2004.
24. Aos S. The Criminal Justice System in Washington State: Incarceration Rates, Taxpayer Costs, Crime Rates, and Prison Economics. Washington State Institute for Public Policy, January 2003.
25. Aos S, Barnoski R. Washington State's Drug Courts For Adult Defendants: Outcome Evaluation And Cost-Benefit Analysis. Washington State Institute for Public Policy, March, 2003.
26. Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS 1999; 10; 13(13): 1745-1751.
27. Marley DS. Decision and cost-effectiveness analysis. J Fam Pract 1990; 30(2): 233-236.
28. Davis JE. Decision analysis: a prescriptive method for decision and cost-effectiveness research. J Fam Pract 1989; 29(4):367-369.
29. McNeil BJ. Changing roles of decision analysis and cost-effectiveness analyses in medicine and radiology. Eur Radiol 2000;10 (Suppl 3): S340-3.
30. Carlos RC, Bree RL, Abrahamse PH, Fendrick AM. Cost-effectiveness of saline-assisted hysterosonography and office hysteroscopy in the evaluation of postmenopausal bleeding: a decision analysis. Acad Radiol 2001; 8(9): 835-44.
31. Palmer CS, Brunner E, Ruiz-Flores LG, Paez-Agraz F, Revicki DA. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Res 2002; 33(6): 572-590.
32. Post PN, Kievit J, van Bockel JH. Optimal follow-up strategies after aorto-iliac prosthetic reconstruction: a decision analysis and cost-effectiveness analysis. Eur J Vasc Endovasc Surg 2004; 28(3): 287-295.
33. Kocher MS, Henley MB. It is money that matters: decision analysis and cost-effectiveness analysis. Clin Orthop Relat Res 2003;(413):106-116.
34. Inadomi JM. Decision analysis and economic modeling: a primer. Eur J Gastroenterol Hepatol 2004;16(6): 535-542.
35. Sonnenberg A. Decision analysis in clinical gastroenterology. Am J Gastroenterol 2004; 99(1): 163-9. Erratum in: Am J Gastroenterol 2004; 99(2): following 398.
36. You JH, Chan FW, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb Haemost 2004; 92(3): 590-597.
37. Targownik LE, Spiegel BM, Sack J, Hines OJ, Dulai GS, Gralnek IM, Farrell JJ. Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. Gastrointest Endosc 2004; 60(6): 865-874.
38. Culligan PJ, Myers JA, Goldberg RP, Blackwell L, Gohmann SF, Abell TD. Elective cesarean section to prevent anal incontinence and brachial plexus injuries associated with macrosomia-a decision analysis. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16(1): 19-28
39. Lejeune C, Al Zahouri K, Woronoff-Lemsi MC, Arveux P, Bernard A, Binquet C, Guillemin F. Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule. Eur J Health Econ 2005; 6(3): 203-214.
40. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. JAMA 1991; 265(22): 2987-2991.
41. Malow RM, West JA, Sutker PB. Anxiety and pain response changes across treatment: sensory decision analysis. Pain 1989; 38(1): 35-44.
42. Bala MV, Zarkin GA. Application of cost-effectiveness analysis to multiple products: a practical guide. Am J Manag Care 2002; 8(3): 211-218.
43. Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol 2000; 35(5): 478-492.
44. Cose E. America's prison generation. Newsweek. November 13, 2000.
45. Belenko SJ, Fagan A, Dumanovsky T. Effects of Legal Sanctions on Recidivism in Special Drug Courts. Justice System Journal 1994; 17: 53-81
46. Andrews DA, Zinger I, Hoge RD, Bonta J, Gendreau P, Cullen FT. Does correctional treatment work? A clinically relevant and psychologically informed meta analysis. Criminology 1990; 28: 3, 369-404.
47. Taxman, F. and B. Yates. Quantitative Exploration of Pandora's Box of Treatment and Supervision: What Goes on Between Costs In and Outcomes Out. In Farrington, D.P., Welsh, B.C. and Sherman, L.W. (Eds.): Preventing Crime: Economic Costs and Benefits. Boulder, CO: Westview Press. In press.
48. Lurigio, Arthur J. Drug treatment availability and effectiveness. Crim Justice Behav 2000; 27(4): 495-528.
49. Inciardi JA, Martin SS, Butzin CA, Hooper RM, Harrison LD. An effective model of prison-based treatment for drug-involved offenders. J Drug Issues 1997; 27: 261-278.
50. Field G. The effects of intensive treatment on reducing the criminal recidivism of addicted offenders. Federal Probation 1989; 53: 51-56.
51. Harwood HJ, Fountain D, Livermore G. Economic costs of alcohol abuse and alcoholism. Recent Dev Alcohol 1998; 14: 307-30.
52. Cropsey KL, Villalobos GC, St Clair CL. Pharmacotherapy treatment in substance-dependent correctional populations: a review. Subst Use Misuse 2005; 40(13-14): 1983-1999; 2043-2048.
53. Knight K, Hiller ML, Simpson DD. Evaluating corrections-based treatment for the drug-abusing criminal offender. J Psychoactive Drugs 1999; 31(3): 299-304.
54. Hubbard RL, Marsden ME. Relapse to use of heroin, cocaine, and other drugs in the first year after treatment. NIDA Res Monogr 1986; 72: 157-166.
55. Broome KM, Knight K, Hiller ML, Simpson DD. Drug treatment process indicators for probationers and prediction of recidivism. J Subst Abuse Treat 1996; 13(6): 487-491.
56. Schermer CR, Moyers TB, Miller WR, Bloomfield LA. Trauma center brief interventions for alcohol disorders decrease subsequent driving under the influence arrests. J Trauma 2006; 60(1): 29-34.
57. Bonta J, Wallace-Capretta S, Rooney J. A quasi-experimental evaluation of an intensive rehabilitation supervision program. Crim Justice Behav 2000; 27(3): 312-329.
58. Jancic M. Does Correctional Education Have an Effect on Recidivism? Journal of Correctional Education 1998; 49 (4): 152-161.
59. Harrell A, Cavanagh S. Preliminary Results from the Evaluation of the DC Superior Court Drug Intervention Program for Drug Felony Defendants. Washington, DC: National Institute of Justice, 1996.
60. Blenko S, Schiff MT, Winterfield P, Winterfield LA. Modeling the prison displacement effects of alternative sanctions programs: a case study. Prison Journal 1994; 74: 2, 167.
61. Quinones MA, Doyle KM, Sheffet A, Louria DB. Evaluation of drug abuse rehabilitation efforts: a review. Am J Public Health 1979; 69(11): 1164-1169.
62. Sambamoorthi U, Warner LA, Crystal S, Walkup J. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug Alcohol Depend 2000; 60(1): 77-89.
63. Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol 2000; 35(5): 478-492.
64. Hoff RA, Rosenheck RA. Cost of treating substance abuse patients with and without comorbid psychiatric disorders. Psychiatr Serv 1999; 50(10): 1309-1315.
65. Fox K, Merrill JC, Chang HH, Califano JA Jr. Estimating the costs of substance abuse to the Medicaid hospital care program. Am J Public Health 1995; 85(1): 48-54.
66. Schildhaus S, Gerstein D, Brittingham A, Cerbone F, Dugoni B. Services research outcomes study: overview of drug treatment population and outcomes. Subst Use Misuse 2000; 35(12-14): 1849-1877.
67. Parthasarathy S, Mertens J, Moore C, Weisner C. Utilization and cost impact of integrating substance abuse treatment and primary care. Med Care 2003;41(3): 357-367.
68. Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94(4): 479-488.
69. Schumacher JE, Mennemeyer ST, Milby JB, Wallace D, Nolan K. Costs and effectiveness of substance abuse treatments for homeless persons. J Ment Health Policy Econ. 2002; 5(1): 33-42.
70. Caton CL, Dominguez B, Schanzer B, Hasin DS, Shrout PE, Felix A, McQuistion H, Opler LA, Hsu E. Risk factors for long-term homelessness: findings from a longitudinal study of first-time homeless single adults. Am J Public Health 2005; 95(10): 1753-1759.
71. Carroll KM. Recent advances in the psychotherapy of addictive disorders. Curr Psychiatry Rep 2005; 7(5): 329-36.
72. Kornor H, Waal H. From opioid maintenance to abstinence: a literature review. Drug Alcohol Rev 2005; 24(3): 267-274.
73. Amato L, Davoli M, A Perucci C, Ferri M, Faggiano F, P Mattick R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28(4): 321-329.
74. Ashley OS, Marsden ME, Brady TM. Effectiveness of substance abuse treatment programming for women: a review. Am J Drug Alcohol Abuse. 2003; 29(1): 19-53.
75. Barnett PG. The cost-effectiveness of substance abuse treatment. Curr Psychiatry Rep 1999; 1(2): 166-171.
76. Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94(4): 479-488.
77. Alemi F, Taxman F, Doyon V, Thanner M, Baghi H. Activity Based Costing of Probation with and without Substance Abuse Treatment: A Case Study. Journal of Mental Health Economics. J Merit Health Policy Econ 2004; 7 (2): 51-7-
78. Goodman AC, Nishiura E, Hankin JR. Short term drug abuse treatment costs and utilization: a multi-employer analysis. Med Care 1998; 36(8): 1214-1227.
79. Anderson DW, Bowland BJ, Cartwright WS, Bassin G. Service-level costing of drug abuse treatment. J Subst Abuse Treat 1998; 15(3): 201-211.
80. Choi BC, Robson L, Single E . Estimating the economic costs of the abuse of tobacco, alcohol and illicit drugs: a review of methodologies and Canadian data sources. Chronic Dis Can 1997; 18(4): 149-165.
81. Cartwright WS. Cost-benefit and cost-effectiveness analysis of drug abuse treatment services. Eval Rev 1998; 22(5): 609-636.
82. French MT, Salome HJ, Carney M. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington. Soc Sci Med 2002; 55(12): 2267-2282.
83. Alemi F, Haack M, Holifield L, Claudio Y, Haqqi K. Unit cost of counseling and patients length of stay in a residential drug treatment setting. J Ment Health Policy Econ 2002; 5(3): 103-107.
84. Alemi F, Sullivan T. An example of activity based costing of treatment programs using time between discharges. Available on 04/18/2006 at http://gunston.doit.gmu.edu/healthscience/NIDA/TreatmentCost.doc
85. Miller TR, Cohen MA, Rossman SB. Victim costs of violent crime and resulting injuries. Health Aff 1993; 12(4): 186-197.
86. Aos S, Phipps P, Barnoski R, Roxanne L. The comparative costs and benefits of programs to reduce crime. Washington State Institute for Public Policy, May 1999.
87. Bauer L. Owens SD. Justice expenditure and Employment in the United States 2001. Bureau of Justice Statistics Bulletin, May 2004. See also http://www.ojp.usdoj.gov/bjs/pub/pdf/jeeus01.pdf, accessed on December 21, 2004.
88. Bauer L, Owens SD. Justice expenditure and Employment in the United States 2001. Bureau of Justice Statistics Bulletin, May 2004.
89. See http://www.cms.hhs.gov/providers/ipfpps/rptcongress.pdf, Report to Congress on Prospective Payment System for Psychiatric Hospitals, 2002. Accessed on December 21, 2004.
90. Cost of Health Insurance," Employer Health Benefits: 2004 Annual Survey of Kaiser Family Foundation, examined on January 23, 2005 at http://www.kff.org/insurancen/7148/index.cfm.
91. Hospital charges based on the period between June 2003 and June 2004. Maryland Health Services Cost Review Commission, Department of Health and Mental Hygiene, State of Maryland, September 1, 2004. See http://www.hscrc.state.md.us/hscrc_publications/pdfs/CPC_MAY_2004.pdf accessed on Monday, January 03, 2005.
92. US Department of Housing and Urban Development. 2004 Fair Market Rents County Level Data Files. See http://www.huduser.org/datasets/FMR/ FMR2004F/FMR2004P_County.xls for Washington, DC-MD- VA-WV PMSA, MSA 8840. Accessed on Wednesday, December 22, 2004.
93. French MT, Zarkin GA, Hubbard RL, Rachal JV. The effects of time in drug abuse treatment and employment on post-treatment drug use and criminal activity. Am J Drug Alcohol Abuse 1993; 19(1): 19-33.
94. Robertson AA, Grimes PW, Rogers KE. A Short-Run Cost-Benefit Analysis of Community-Based Interventions for Juvenile Offenders. Crime & Delinquency 2001; 47 (2): 265-285.
95. Fass SM, Pi CR. Getting Tough on Juvenile Crime: An Analysis of Costs and Benefits. Journal of Research in Crime and Delinquency 2002; 39: 363-399.